Non-hermitean delocalization in an array of wells with variable-range widths

Nonhermitean hamiltonians of convection-diffusion type occur in the description of vortex motion in the presence of a tilted magnetic field as well as in models of driven population dynamics. We study such hamiltonians in the case of rectangular barriers of variable size. We determine Lyapunov exponent and wavenumber of the eigenfunctions within an adiabatic approach, allowing to reduce the original d=2 phase space to a d=1 attractor. PACS numbers:05.70.Ln,72.15Rn,74.60.GeComment: 20 pages,10 figure

Structure of the French farm-to-table surveillance system for Salmonella

The French surveillance system for Salmonella is based on a national system which can be traced back to 1947 for human cases and to the late 1980s for the main animal reservoirs. This system has evolved with regard to both European regulations and changes in the observed prevalence of Salmonella. European regulations establish a solid foundation on which to build an active harmonised surveillance system at the production level and for integrating data from the whole food chain. There are also passive surveillance networks in the agri-food and veterinary sectors and these allow complementary information to be obtained from other sectors or sources. The main strengths and weaknesses of these systems are described and a comparison of the different approaches is presented using a grid analysis. The results show that passive systems are very useful for detecting emerging or unusual events and for early warning of outbreaks. They also produce time series of cases or can determine the number of strains that should be used to assess the impact of interventions. Active surveillance data, due to their representativeness and reliability, are key elements in the application of risk analysis tools such as quantitative risk assessment or attribution. Thus, although data is collected and analysed by various organisations, these organisations all collaborate at a national level. Furthermore, their implication in European and international projects is effective and the main objectives of a surveillance system can be met

Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

BACKGROUND: Recombinant human erythropoietin (EPO) is used for the treatment of last stage renal anemia. A new EPO preparation was obtained in Cuba in order to make this treatment fully nationally available. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety properties of two recombinant EPO formulations in patients with anemia due to end-stage renal disease on hemodialysis. METHODS: A parallel, randomized, double blind study was performed. A single 100 IU/Kg EPO dose was administered subcutaneously. Heberitro (Heber Biotec, Havana, formulation A), a newly developed product and Eprex (CILAG AG, Switzerland, formulation B), as reference treatment were compared. Thirty-four patients with anemia due to end-stage renal disease on hemodialysis were included. Patients had not received EPO previously. Serum EPO level was measured by enzyme immunoassay (EIA) during 120 hours after administration. Clinical and laboratory variables were determined as pharmacodynamic and safety criteria until 216 hours. RESULTS: Both groups of patients were similar regarding all demographic and baseline characteristics. EPO kinetics profiles were similar for both formulations; the pharmacokinetic parameters were very close (i.e., AUC: 4667 vs. 4918 mIU.h/mL; Cmax: 119.1 vs. 119.7 mIU/mL; Tmax: 13.9 vs. 18.1 h; half-life, 20.0 vs. 22.5 h for formulations A and B, respectively). The 90% confidence intervals for the ratio between both products regarding these metrics were close to the 0.8 – 1.25 range, considered necessary for bioequivalence. Differences did not reach 20% in any case and were not determined by a formulation effect, but probably by a patients' variability effect. Concerning pharmacodynamic features, a high similitude in reticulocyte counts increments until 216 hours and the percentage decrease in serum iron until 120 hours was observed. There were no differences between formulations regarding the adverse events and their intensity. The more frequent events were pain at injection site (35.3%) and hypertension (29%). Additionally, further treatment of the patients with the study product yielded satisfactory increases in hemoglobin and hematocrit values. CONCLUSION: The formulations are comparable. The newly developed product should be acceptable for long-term application